Hyperplasia News and Research

RSS

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

China PharmaHub Corp., recently merged with World Wide Relics, which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China.

18 Aug 2010

Nymox second-quarter net loss increases to $1.75 million

Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.

16 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today the company received CE Mark for AdVance XP. The device is the latest generation of AMS' AdVance sling, a minimally invasive implant for the treatment of male stress urinary incontinence (SUI).

9 Aug 2010

NeoTract selects SYSPRO ERP

SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that NeoTract, Inc., a Medical Device start-up company headquartered in Pleasanton, Calif., has selected SYSPRO ERP (Enterprise Resource Planning) software to manage the company's financial, manufacturing and distribution operations.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

Researchers recommend six steps for shared decision making in sex development disorder surgery

A shared decision-making process would assist doctors and parents who are facing the extraordinarily complex, challenging and controversial choices presented when infants are born with genetic or anatomical anomalies in sexual development and are being considered for elective corrective surgery, a new research paper suggests.

26 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

USFDA approves Sun Pharma's generic Flomax ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for its Abbreviated New Drug Application to market a generic version of Flomax ®, tamsulosin capsules.

16 Jul 2010

Study links high-fat diet as potential cause of prostatic diseases

Prostate cancer is the second leading cause of cancer-related deaths in men with an estimated 192,280 new cases diagnosed in the US in 2009 (Jemal 2009). Diet is considered one of the most important controllable risk factors for inflammation and prostate diseases including benign prostatic hyperplsia, prostatitis, and prostate cancer.

15 Jul 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Surgery more beneficial than drug therapy for benign prostatic hyperplasia

A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic.

31 May 2010

Clinical abstracts on Urologix' Cooled ThermoTherapy selected for presentation at AUA's GUS meeting

Urologix®, Inc., a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting's sub-specialty society, the Geriatric Urological Society (GUS) meeting.

29 May 2010